Prescribing gabapentin off label: Perspectives from psychiatry, pain and neurology specialists

Canadian Pharmacists Journal

Volumn 145, Issue 6, 2012, Pages 280-284

  Fukada, Christine ^a   Kohler, Jillian Clare ^a   Boon, Heather ^a   Austin, Zubin ^a   Krahn, Murray ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN;

CANADA; EVIDENCE BASED PRACTICE; HUMAN; NEUROLOGIST; OFF LABEL DRUG USE; PATIENT SAFETY; PRESCRIPTION; PSYCHIATRIST; REVIEW; SEMI STRUCTURED INTERVIEW; TREATMENT OUTCOME;

EID: 84869448104     PISSN: 17151635     EISSN: 1913701X     Source Type: Journal    
DOI: 10.3821/145.6.cpj280     Document Type: Review

References (27)

1. Boos J. Off label use-label off use? Ann Oncol 2003;14:1-5.
2. Klein DB, Tabarrok A. Who certifies off-label? Regulation 2004;27:60-3. Available: www.cato.org/pubs/regulation/ regv27n2/v27n2-8.pdf (accessed January 29, 2005).
3. Nightingale SL. Off-label use of prescription drugs. Am Fam Physician 2003;68:425-7.
4. Gazarian M, Kelly M, McPhee JR, et al. Off-label uses of medicines: consensus recommendations for evaluating appropriateness. Med J Aust 2006;185:544-8.
5. Stone KJ, Viera AJ, Parman CL. Off-label applications for SSRIs. Am Fam Physician 2003;68:498-504.
6. Haw C, Stubbs J. A survey of the off-label use of mood stabilizers in a large psychiatric hospital. J Psychopharmacol 2005;19:402-7.
7. Serradell J, Galle B. Prescribing for unlabeled indications. HMO Practice 1993;7:44-7.
8. Kos M, Wertheimer AI, Mrhar A. Satisfaction with pharmacotherapy for approved and off-label indications-a Delphi study. Ann Pharmacother 2005;39:649-54.
9. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006;166:1021-6.
10. MacLeod SM. Improving physician prescribing practices: bridge over troubled waters. CMAJ 1996;154:675-7.
11. Neurontin [product monograph]. Kirkland (PQ): Pfizer Canada Inc.; 2011. Available: www.pfizer.ca/en/our_products/ products/monograph/128 (accessed August 3, 2012).
12. Health Canada. Notice of compliance database. Available: http://webprod3.hc-sc.gc.ca/noc-ac/index-eng.jsp (accessed August 3, 2012).
13. Neurontin [prescribing information]. September 2011. Available: www.pfizer.com/files/products/uspi_neurontin. pdf (accessed January 15, 2008).
14. Mack A. Examination of the evidence for off-label use of gabapentin. J Manag Care Pharm 2003;9:559-68.
15. Davis S. Gabapentin may be appropriate for off-label uses. J Manag Care Pharm 2003;9:569-70.
16. Kaufman R. The Neurontin controversy: the saga of off-label drug regulation continues. 2004. Legal Electronic Document Archive (LEDA), Harvard University. Available: http://leda.law.harvard.edu/leda/search/toc. php3?handle=HLS.Library.Leda/kaufmanr-neurontin_ controversy_saga.
17. Gilpin KN. Pfizer to pay $420 million in illegal marketing case. New York Times. May 13, 2004. Available: www.nytimes.com/2004/05/13/business/13CND-DRUG. html?ex=1109480400&en=4dd23f1f49307710&ei=507 0&hp (accessed January 15, 2008).
18. Stake RE. Case studies. In: Denzin NK, Lincoln YS, eds. Handbook of qualitative research. 2nd edition. Thousand Oaks (CA): Sage Publications; 2000:435-54.
19. Weber RP. Basic content analysis. 2nd edition. Series: quantitative applications in the social sciences. London: Sage Publications; 1990:5-12.
20. Creswell JW. Qualitative inquiry & research design: choosing among five approaches. 2nd edition. Thousand Oaks (CA): Sage Publications; 2007.
21. Generali JA. Off-label drug facts. Basic bibliographies. Hosp Pharm 2002;37:684-9, 696.
22. Lewis PJ, Tully MP. Uncomfortable prescribing decisions in hospitals: the impact of teamwork. J R Soc Med 2009;102:481-8.
23. Mason A. New medicines in primary care: a review of influences on general practitioner prescribing. J Clin Pharm Ther 2008;33:1-10.
24. Prosser H, Almond S, Walley T. Influences on GPs' decision to prescribe new drugs-the importance of who says what. Fam Pract 2003;20:61-8.
25. Chin MH, Friedmann PD, Cassel CK, Lang RM. Differences in generalist and specialist physicians' knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure. J Gen Intern Med 1997;12:523-30.
26. Greer AL. The state of the art versus the state of the science. The diffusion of new medical technologies into practice. Int J Technol Assess Health Care 1988;4:5-26.
27. Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain-consensus statement and guidelines from the Canadian Pain Society. Pain Res Manage 2007;12:13-21.